Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

gainst products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. 

Contacts:

Onyx Pharmaceuticals, Inc.
Danielle Bertrand (media)
1-650-266-2114

Amgen
Ashleigh Koss, 1-805-313-6151 (media)
Arvind Sood, 1-805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20131107/LA12955LOGO)


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Baylor Research Institute (BRI) ... Translational Genomics Research Institute (TGen) in Phoenix, ... on accelerating early detection and treatments for patients with a ... institutions will lead to new clinical trials and access to ... the gap from bench to bedside across Baylor Scott ...
(Date:5/21/2015)... 21, 2015  Susan Hedstrom, Executive Director of ... organization dedicated to supporting research to advance the ... today that FPWR has received the organization,s largest ... contributed $1 million in support of the ... "Our gift signifies our ...
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3
... Communications, an,innovator in medical communications, brand development, ... to serve the company,s growing,client base in ... Palmisano, the new vice president of medical ... it integrates creative thinking,and scientific acumen to ...
... Modeling Complex ... Biological Systems for Type 2 Diabetes, CAMBRIDGE, Mass., ... on identifying molecular mechanisms, networks and,biomarkers to better understand ... Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ),a biopharmaceutical company ...
... Shandong, China, April 30 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... or "the,Company"), one of the leading plasma-based ... ("PRC"), today announced that the Company,received approval ... Administration,("SFDA") (1) to start the production of ...
Cached Biology Technology:MedThink Hires Two Executives to Serve its Growing Pharmaceutical Client Base 2Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 2China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 3
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... release is available in German . , It ... the fate of individual cells during the early development of ... team of molecular biologists led by Pia Aanstad of the ... accounts for the interpretation of the concentration of the signaling ...
... patient,s body, stem cells intended to treat or cure ... they are no longer under the control of the ... solve this problem, according to a perspective article from ... a recent issue of the journal Cell Stem ...
... the time of the Babylonians to the Incas, terracing ... and hilly croplands. Designing terrace layouts can be time ... are developing a Web-based program that will design multiple ... will help farm experts choose the most efficient and ...
Cached Biology News:Why the thumb of the right hand is on the left hand side 2Gene therapy could expand stem cells' promise 2Web-based program designs more efficient farm terrace layouts 2